Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Patients with Relapsing Remitting Multiple Sclerosis

Next Previous
Trial Profile

Comparison of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Patients with Relapsing Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary) ; Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 28 Oct 2017 Results of patterns of regional gray matter and white matter atrophy (n=55) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
  • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
  • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top